JCO at WCLC: Multinational Pivotal Study of Sunvozertinib in Exon20ins NSCLC

<p><span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;">JCO fellow Dr. Ece Cali speaks with JCO Associate Editor Dr. Thomas E. Stinchcombe to discuss the JCO article <a href= "https://ascopubs.org/doi/10.1200/JCO-25-00788" target="_blank" rel="noopener">"Phase 2 Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)"</a>, that was simultaneously released at the IASLC 2025 World Conference on Lung Cancer.</span></p> <p class="MsoNormal" style="margin: 12pt 0in; text-align: left;" align="center"><span style= "text-decoration: underline; font-size: 12pt; font-family: arial, helvetica, sans-serif;"> <strong>TRANSCRIPT</strong></span></p> <p class="MsoNormal" style="margin: 12.0pt 0in 12.0pt 0in;"> <span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;"><strong style="mso-bidi-font-weight: normal;"> <span lang="EN" xml:lang="EN">Dr. Ece Cal...